Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of “Buy” by Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have been assigned an average rating of “Buy” from the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $34.00.

Several brokerages recently issued reports on RCUS. Wells Fargo & Company began coverage on shares of Arcus Biosciences in a research report on Tuesday, October 8th. They set an “overweight” rating and a $29.00 price target on the stock. Barclays upped their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th. HC Wainwright reissued a “neutral” rating and set a $20.00 price target on shares of Arcus Biosciences in a research report on Wednesday, November 6th. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Arcus Biosciences in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a report on Thursday, October 3rd.

Arcus Biosciences Price Performance

Shares of RCUS opened at $15.83 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. Arcus Biosciences has a twelve month low of $13.52 and a twelve month high of $20.31. The firm’s 50 day moving average price is $16.19 and its 200 day moving average price is $16.06. The firm has a market cap of $1.45 billion, a PE ratio of -5.03 and a beta of 0.88.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.06. The company had revenue of $48.00 million for the quarter, compared to the consensus estimate of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company’s revenue for the quarter was up 50.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.94) EPS. As a group, research analysts expect that Arcus Biosciences will post -3.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Arcus Biosciences

Hedge funds have recently bought and sold shares of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in Arcus Biosciences by 8.7% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 744,298 shares of the company’s stock worth $11,336,000 after acquiring an additional 59,273 shares during the last quarter. Jane Street Group LLC raised its holdings in Arcus Biosciences by 59.8% in the 3rd quarter. Jane Street Group LLC now owns 217,041 shares of the company’s stock valued at $3,319,000 after acquiring an additional 81,193 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Arcus Biosciences by 11.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 566,979 shares of the company’s stock valued at $8,669,000 after acquiring an additional 59,536 shares during the period. GSA Capital Partners LLP grew its holdings in shares of Arcus Biosciences by 17.8% during the 3rd quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock worth $2,866,000 after purchasing an additional 28,307 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Arcus Biosciences in the second quarter worth $1,286,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.